ExodusPoint Capital Management LP purchased a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 134,680 shares of the company's stock, valued at approximately $423,000. ExodusPoint Capital Management LP owned 0.13% of Acelyrin as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of Acelyrin in the third quarter worth approximately $50,000. HighTower Advisors LLC purchased a new position in shares of Acelyrin in the third quarter worth $50,000. Intech Investment Management LLC boosted its position in shares of Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock valued at $83,000 after buying an additional 11,040 shares during the last quarter. American Century Companies Inc. increased its holdings in Acelyrin by 146.0% in the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company's stock worth $248,000 after buying an additional 46,802 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Acelyrin by 208.8% during the third quarter. Barclays PLC now owns 96,408 shares of the company's stock valued at $475,000 after purchasing an additional 65,188 shares during the last quarter. 87.31% of the stock is currently owned by hedge funds and other institutional investors.
Acelyrin Stock Performance
Shares of SLRN remained flat at $2.20 during trading hours on Friday. 692,536 shares of the stock were exchanged, compared to its average volume of 1,222,461. The stock has a market capitalization of $222.00 million, a price-to-earnings ratio of -0.89 and a beta of 1.12. Acelyrin, Inc. has a 1 year low of $1.85 and a 1 year high of $7.25. The stock has a 50-day moving average of $2.45 and a two-hundred day moving average of $3.48.
Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.07. On average, equities analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current year.
Insider Activity at Acelyrin
In related news, CEO Mina Kim sold 17,986 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the sale, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.60% of the stock is owned by insiders.
Wall Street Analyst Weigh In
SLRN has been the topic of several recent analyst reports. Citigroup decreased their target price on Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reduced their target price on Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $9.60.
Read Our Latest Analysis on SLRN
Acelyrin Company Profile
(
Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Stories
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
